AU2015337807B2 - Detection and treatment of excessive hair shedding - Google Patents

Detection and treatment of excessive hair shedding Download PDF

Info

Publication number
AU2015337807B2
AU2015337807B2 AU2015337807A AU2015337807A AU2015337807B2 AU 2015337807 B2 AU2015337807 B2 AU 2015337807B2 AU 2015337807 A AU2015337807 A AU 2015337807A AU 2015337807 A AU2015337807 A AU 2015337807A AU 2015337807 B2 AU2015337807 B2 AU 2015337807B2
Authority
AU
Australia
Prior art keywords
range
concentration
hair
minoxidil
shedding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015337807A
Other languages
English (en)
Other versions
AU2015337807A1 (en
Inventor
Rodney Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samson Clinical Pty Ltd
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55856287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015337807(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904327A external-priority patent/AU2014904327A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of AU2015337807A1 publication Critical patent/AU2015337807A1/en
Application granted granted Critical
Publication of AU2015337807B2 publication Critical patent/AU2015337807B2/en
Priority to AU2017210523A priority Critical patent/AU2017210523B2/en
Priority to AU2018279055A priority patent/AU2018279055A1/en
Priority to AU2020203695A priority patent/AU2020203695B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015337807A 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding Active AU2015337807B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017210523A AU2017210523B2 (en) 2014-10-29 2017-08-01 Detection and treatment of excessive hair shedding
AU2018279055A AU2018279055A1 (en) 2014-10-29 2018-12-17 Detection and treatment of excessive hair shedding
AU2020203695A AU2020203695B2 (en) 2014-10-29 2020-06-04 Detection and treatment of excessive hair shedding

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904327 2014-10-29
AU2014904327A AU2014904327A0 (en) 2014-10-29 Detection and treatment of excessive hair shedding
PCT/AU2015/050682 WO2016065426A1 (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017210523A Division AU2017210523B2 (en) 2014-10-29 2017-08-01 Detection and treatment of excessive hair shedding

Publications (2)

Publication Number Publication Date
AU2015337807A1 AU2015337807A1 (en) 2017-04-13
AU2015337807B2 true AU2015337807B2 (en) 2017-05-04

Family

ID=55856287

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015337807A Active AU2015337807B2 (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding
AU2017210523A Active AU2017210523B2 (en) 2014-10-29 2017-08-01 Detection and treatment of excessive hair shedding
AU2018279055A Abandoned AU2018279055A1 (en) 2014-10-29 2018-12-17 Detection and treatment of excessive hair shedding
AU2020203695A Active AU2020203695B2 (en) 2014-10-29 2020-06-04 Detection and treatment of excessive hair shedding

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017210523A Active AU2017210523B2 (en) 2014-10-29 2017-08-01 Detection and treatment of excessive hair shedding
AU2018279055A Abandoned AU2018279055A1 (en) 2014-10-29 2018-12-17 Detection and treatment of excessive hair shedding
AU2020203695A Active AU2020203695B2 (en) 2014-10-29 2020-06-04 Detection and treatment of excessive hair shedding

Country Status (11)

Country Link
US (2) US10226462B2 (enExample)
EP (2) EP3626244B1 (enExample)
JP (2) JP6915946B2 (enExample)
KR (2) KR102625061B1 (enExample)
CN (2) CN107106560A (enExample)
AU (4) AU2015337807B2 (enExample)
CA (2) CA3209849A1 (enExample)
ES (2) ES2952159T3 (enExample)
NZ (1) NZ732075A (enExample)
SG (2) SG10202002705YA (enExample)
WO (1) WO2016065426A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102625061B1 (ko) 2014-10-29 2024-01-16 삼손 클리니컬 피티와이 엘티디 과도한 모발 쉐딩의 검출 및 치료
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20180189976A1 (en) 2016-12-29 2018-07-05 Michal Kasprzak Analysis unit and system for assessment of hair condition
WO2019010535A1 (en) * 2017-07-12 2019-01-17 Samson Clinical Pty Ltd STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA
JP7777448B2 (ja) * 2018-09-13 2025-11-28 エイリオン セラピューティクス， インコーポレイテッド プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ－１）阻害剤（ｉｎｈｉｂｉｔｏｒ）の使用
CN109674762A (zh) * 2019-03-05 2019-04-26 南京正大天晴制药有限公司 一种度他雄胺及治疗脱发的组合物胶囊
CN110478450B (zh) * 2019-10-09 2021-04-13 北海鑫臻药业有限公司 一种治疗阿尔茨海默病的药物组合物及其应用
CN111110721A (zh) * 2020-01-19 2020-05-08 朱炜 一种毛发防脱再生的复合制剂及其使用方法
WO2021172060A1 (ja) * 2020-02-27 2021-09-02 パナソニックＩｐマネジメント株式会社 画像処理装置及び画像処理方法
US12622907B2 (en) 2021-09-29 2026-05-12 Nirmana Health, Inc. Hair loss therapy
US11744788B2 (en) * 2021-10-27 2023-09-05 James D. Welch Method of encouraging growth and regrowth of hair in human males technical area
JP2025536556A (ja) * 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
CN119947694A (zh) * 2023-09-01 2025-05-06 芙丽亚国际公司 用于治疗脱发症的口服米诺地尔的口服补充剂的方法和组合物
US20250213594A1 (en) * 2023-12-27 2025-07-03 Inventage Lab Inc. Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018936A1 (en) * 1993-02-19 1994-09-01 Ringler, Steven, L. Compositions and methods for promoting hair growth
US20080064765A1 (en) * 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1992008705A1 (en) * 1990-11-14 1992-05-29 The Upjohn Company 5-fluoro-2,4,6-pyrimidinetriamine compounds
GB2314019B (en) 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
WO1999040898A2 (en) 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
JP2000038340A (ja) 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2003012542A (ja) 2001-06-26 2003-01-15 Toray Ind Inc 発毛促進剤
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CN1838969A (zh) 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
US8110655B2 (en) * 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
WO2013181487A2 (en) 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
KR102625061B1 (ko) 2014-10-29 2024-01-16 삼손 클리니컬 피티와이 엘티디 과도한 모발 쉐딩의 검출 및 치료
US9561224B1 (en) 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia
WO2019010535A1 (en) 2017-07-12 2019-01-17 Samson Clinical Pty Ltd STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018936A1 (en) * 1993-02-19 1994-09-01 Ringler, Steven, L. Compositions and methods for promoting hair growth
US20080064765A1 (en) * 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens

Also Published As

Publication number Publication date
US20190192513A1 (en) 2019-06-27
AU2020203695B2 (en) 2021-09-02
CA3003940A1 (en) 2016-05-06
US11116770B2 (en) 2021-09-14
AU2015337807A1 (en) 2017-04-13
ES2952159T3 (es) 2023-10-27
AU2018279055A1 (en) 2019-01-17
AU2020203695A1 (en) 2020-06-25
CN107106560A (zh) 2017-08-29
HK1243641A1 (en) 2018-07-20
NZ732075A (en) 2022-09-30
EP3626244A1 (en) 2020-03-25
EP3626244B1 (en) 2023-06-07
JP2017533265A (ja) 2017-11-09
KR20240011239A (ko) 2024-01-25
AU2017210523A1 (en) 2017-08-17
US20170333432A1 (en) 2017-11-23
AU2017210523B2 (en) 2018-11-15
ES2773467T3 (es) 2020-07-13
JP6915946B2 (ja) 2021-08-11
EP3212192A1 (en) 2017-09-06
EP3212192B1 (en) 2019-11-20
CN115998740A (zh) 2023-04-25
CA3003940C (en) 2023-10-10
CA3209849A1 (en) 2016-05-06
SG11201703424WA (en) 2017-05-30
JP2020109127A (ja) 2020-07-16
KR102625061B1 (ko) 2024-01-16
US10226462B2 (en) 2019-03-12
SG10202002705YA (en) 2020-05-28
WO2016065426A1 (en) 2016-05-06
EP3212192A4 (en) 2018-07-04
KR20170102214A (ko) 2017-09-08

Similar Documents

Publication Publication Date Title
AU2020203695B2 (en) Detection and treatment of excessive hair shedding
Asghar et al. Telogen effluvium: a review of the literature
Moftah et al. Mesotherapy using dutasteride‐containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation
Singal et al. Female pattern hair loss
Olsen et al. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo
JP2004500353A (ja) アンドロゲン性およびび慢性脱毛症の治療のためのメラトニンの使用
Torres Androgenetic, diffuse and senescent alopecia in men: practical evaluation and management
HK40023042A (en) Oral minoxidil for the treatment of alopecia areata
HK40023042B (en) Oral minoxidil for the treatment of alopecia areata
Lubov et al. Central centrifugal cicatricial alopecia in Black men: A case series highlighting key clinical features in this cohort
HK1243641B (en) Oral minoxidil for the treatment of telogen effluvium
Sinclair et al. Fast facts: disorders of the hair and scalp
Katoulis et al. Frontal fibrosing alopecia
de Oliveira Community Pharmacy and Hospital Pharmacy Internship Reports and Monograph" Counseling for Androgenetic Alopecia-The Pharmacist's Role"
Piraccini et al. Effectiveness and Safety of Topical Finasteride for Male Androgenetic Alopecia: Real World Data
Hamzeh et al. Common Causes of Hair Loss
Sinha et al. Hair Disorders in Females
Carter Interventions for female pattern hair loss
Roberts Geriatric hair and scalp disorders
Time et al. Advances in the evaluation and treatment of unwanted hair growth (PCOS mentioned)
Mulinari-Brenner Shedding: a common cause of hair loss Wilma F. Bergfeld, MD, FACP Head, Clinical Research, Department of Dermatology The Cleveland Clinic Foundation Address: 9500 Euclid Avenue

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)